Quick Answer
UNITED THERAPEUTICS Corp reported Operating Income Loss of $1.49 billion for the year ending 2025.
- UNITED THERAPEUTICS Corp showed an increase of +8.4% in Operating Income Loss from 2024 to 2025.
- This data is from UNITED THERAPEUTICS Corp's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2010: $32.25 million | Q2 2010: $61.22 million | Q3 2010: $62.49 million | Q1 2011: $36.80 million | Q2 2011: $114.49 million | Q3 2011: $102.98 million | Q1 2012: $106.74 million | Q2 2012: $105.59 million | Q3 2012: $80.72 million | Q1 2013: $94.04 million | Q2 2013: $122.30 million | Q3 2013: $104.65 million | Q1 2014: $216.14 million | Q2 2014: $176.32 million | Q3 2014: -$32.24 million | Q1 2015: -$14.80 million | Q2 2015: $171.80 million | Q3 2015: $387.00 million | Q1 2016: $363.70 million | Q2 2016: $285.20 million | Q3 2016: $238.60 million | Q1 2017: $263.60 million | Q2 2017: $88.50 million | Q3 2017: $323.80 million | Q1 2018: $306.90 million | Q2 2018: $217.40 million | Q3 2018: $149.60 million | Q1 2019: -$655.90 million | Q2 2019: $221.40 million | Q3 2019: $183.40 million | Q1 2020: $166.70 million | Q2 2020: $140.50 million | Q3 2020: $221.10 million | Q1 2021: -$64.80 million | Q2 2021: $222.20 million | Q3 2021: $228.70 million | Q1 2022: $288.00 million | Q2 2022: $201.80 million | Q3 2022: $314.30 million | Q1 2023: $284.40 million | Q2 2023: $313.40 million | Q3 2023: $327.00 million | Q1 2024: $356.30 million | Q2 2024: $319.90 million | Q3 2024: $343.10 million | Q1 2025: $382.80 million | Q2 2025: $364.50 million | Q3 2025: $388.50 million.
- Over the full 18 years of available data (2008 to 2025), UNITED THERAPEUTICS Corp's Operating Income Loss has grown by 1,918.9%.
- Historical annual values: Fiscal year 2025: $1.49 billion | Fiscal year 2024: $1.38 billion | Fiscal year 2023: $1.18 billion | Fiscal year 2022: $979.70 million | Fiscal year 2021: $555.90 million | Fiscal year 2020: $593.60 million | Fiscal year 2019: -$187.60 million | Fiscal year 2018: $805.40 million | Fiscal year 2017: $814.90 million | Fiscal year 2016: $1.06 billion | Fiscal year 2015: $699.00 million | Fiscal year 2014: $538.80 million | Fiscal year 2013: $292.50 million | Fiscal year 2012: $421.65 million | Fiscal year 2011: $317.78 million | Fiscal year 2010: $171.31 million | Fiscal year 2009: $25.76 million | Fiscal year 2008: -$82.06 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: